Investigating the immune profile of AML patients treated with azacitidine and venetoclax
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy: Opportunities for T-Cell Directed Immunotherapy
Mayo Clinic · NCT06279572
This study looks at how the immune system of adults with acute myeloid leukemia responds to treatment with azacitidine and venetoclax to help improve future therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic (other) |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Scottsdale, Arizona and 2 other locations) |
| Trial ID | NCT06279572 on ClinicalTrials.gov |
What this trial studies
This observational study examines the immune profile of adults with acute myeloid leukemia (AML) who are receiving induction chemotherapy with azacitidine and venetoclax. By collecting blood samples and bone marrow aspirates, researchers aim to understand how the immune system responds to this treatment. The study will also evaluate clinical responses based on different immune subtypes of AML. The findings may inform future immune-based treatment strategies for AML patients.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with a diagnosis of treatment-naive acute myeloid leukemia receiving azacitidine and venetoclax.
Not a fit: Patients receiving azacitidine and venetoclax as salvage therapy or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for AML by leveraging immune responses.
How similar studies have performed: Other studies have shown promise in understanding immune profiles in cancer treatments, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults \> 18 yrs of age with diagnosis of acute myeloid leukemia who received azacitidine plus venetoclax chemotherapy * Treatment naive adult acute myeloid leukemia patients Exclusion Criteria: * Acute myeloid leukemia patients receiving azacitidine and venetoclax as salvage therapy will be excluded * Patients who are pregnant or breast-feeding
Where this trial is running
Scottsdale, Arizona and 2 other locations
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States (NOT_YET_RECRUITING)
- Mayo Clinic in Florida — Jacksonville, Florida, United States (RECRUITING)
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (NOT_YET_RECRUITING)
Study contacts
- Principal investigator: Talha Badar, M.D. — Mayo Clinic
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Myeloid Leukemia